Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity
- Design
- Systematic review · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: the review covers adults with type 2 diabetes mellitus or obesity, and the randomized evidence it rests on came from trials with psychiatric exclusion criteria; no BMI or age values are reported.
- Could weight loss explain it?
- UnlikelyUnlikely: the main result is null, so there is no effect to attribute to weight loss or metabolic change. No weight, HbA1c or mediation analysis is reported either.
- Study tier
- Not ratedNOT_RATED: a systematic review with a narrative synthesis only. It appraises risk of bias with RoB 2 and ROBINS-I and summarises certainty with GRADE, but pools nothing itself and reports no new primary outcome data.
- Assessment
- Version 2 · Two independent AI reviews agreed · Nov 6, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
A systematic review searched four databases to March 15, 2026 and brought together twenty studies and two regulatory reviews on whether GLP-1 receptor agonists and tirzepatide raise neuropsychiatric risk in adults with type 2 diabetes or obesity. Randomised evidence, including two large 2025 meta-analyses, showed no increased risk of suicidality, depression or anxiety, and cohort studies with active comparators showed no clear increase once confounding was controlled. Analyses using passive comparators or spontaneous reports did produce signals, which the authors could not separate from existing psychiatric risk, obesity-related distress or reporting bias. The review pools nothing of its own, and the trials it draws on excluded people with psychiatric illness, so it does not settle the question for that group.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists, Tirzepatide
- Dose
- various
- Comparator
- active comparators in the comparative cohorts and target-trial emulations; passive comparators in the disproportionality analyses
- Primary outcome
- neuropsychiatric safety: suicidality, depression and anxiety
- Effect
- No pooled estimate or numerical result is reported. Randomized evidence, including two large 2025 meta-analyses and post hoc pooled analyses of semaglutide and tirzepatide, showed no increased risk of suicidality, depression or anxiety; active-comparator cohorts from the United States, Scandinavia and the United Kingdom showed no clear increase after confounding control; passive-comparator and disproportionality analyses generated signals that could not be separated from baseline psychiatric risk, obesity-related distress or reporting bias.
- 95% confidence interval
- not reported in abstract
- Follow-up
- Not stated
- Adverse events
- The review's subject is safety: randomized evidence showed no increased risk of suicidality, depression or anxiety, active-comparator cohorts showed no clear increase after confounding control, and passive-comparator and disproportionality analyses generated signals the authors could not separate from baseline psychiatric risk, obesity-related distress or reporting bias.
- Limitations
- A narrative synthesis of twenty studies and two regulatory reviews with no pooled estimate of its own; the randomized evidence came from trials with psychiatric exclusion criteria, which the authors say limits generalizability, and they note that surveillance is still needed for people with substantial psychiatric morbidity, for obesity-only populations and for long-term rare outcomes.
Who was studied
- Age min
- 18
- Obesity status
- mixed (the review covers adults with type 2 diabetes mellitus or obesity)
- Diabetes status
- mixed (the review covers adults with type 2 diabetes mellitus or obesity)
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- type 2 diabetes mellitus or obesity
- Inclusion exclusion
- studies in adults aged 18 and over with type 2 diabetes mellitus or obesity, English language, searched through March 15, 2026; evidence grouped into randomized syntheses, comparative observational studies and target-trial emulations, outlier non-active-comparator studies, pharmacovigilance analyses and regulatory reviews
Study quality details
- Study design
- Systematic review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- active comparators in the comparative cohorts and target-trial emulations; passive comparators in the disproportionality analyses
- Follow up duration
- not stated
- Outcome type
- hard
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no pooled estimate, confidence interval or event count reported; risk of bias appraised with Cochrane Risk of Bias 2 and ROBINS-I and certainty summarized with GRADE
- Risk of bias
- not assessed
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[OBJECTIVE] Neuropsychiatric safety concerns about glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and tirzepatide prompted regulatory review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). We synthesized the contemporary evidence in adults with type 2 diabetes mellitus or obesity, emphasizing study design, risk of bias, and the distinction between signal detection and causal inference. [METHODS] The PubMed/MEDLINE, Embase, Web of Science, and Scopus databases were searched without a lower date limit through March 15, 2026 (English, adults ≥18 years). The review was reported with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020, and the PRISMA-S and PRISMA-Harms extensions. Evidence was grouped into prespecified categories: randomized syntheses, comparative observational studies and target-trial emulations, outlier non-active-comparator studies, pharmacovigilance analyses, and regulatory reviews. Risk of bias was appraised with the Cochrane Risk of Bias 2 tool and with Risk of Bias in Non-randomised Studies of Interventions; certainty was summarized using Grading of Recommendations Assessment, Development and Evaluation. [RESULTS] Twenty studies and two regulatory reviews met the inclusion criteria. Randomized evidence, including two large 2025 meta-analyses and post hoc pooled analyses of semaglutide and tirzepatide, showed no increased risk of suicidality, depression, or anxiety, though psychiatric exclusion criteria limited generalizability. Active-comparator cohorts from the United States, Scandinavia, and the United Kingdom likewise showed no clear increase after confounding control. Passive-comparator and disproportionality analyses generated signals but could not separate drug effects from baseline psychiatric risk, obesity-related distress, or reporting bias. The EMA and FDA conclusions do not support a causal class-wide association between GLP-1 RAs and suicidal ideation or behavior. [CONCLUSIONS] Evidence does not support a clinically meaningful increase in neuropsychiatric harm with GLP-1 RAs or tirzepatide in the populations studied. Surveillance remains warranted for patients with substantial psychiatric morbidity, for obesity-only populations, and for long-term rare outcomes.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Nov 1, 2026 | 42957176 first ingestion |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| pubmed | Nov 8, 2026 | 42957176 duplicate matched on doi |